FB Hagemeister

1.6k total citations · 1 hit paper
18 papers, 1.3k citations indexed

About

FB Hagemeister is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, FB Hagemeister has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 7 papers in Neurology. Recurrent topics in FB Hagemeister's work include Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (7 papers) and CNS Lymphoma Diagnosis and Treatment (7 papers). FB Hagemeister is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (7 papers) and CNS Lymphoma Diagnosis and Treatment (7 papers). FB Hagemeister collaborates with scholars based in United States. FB Hagemeister's co-authors include Fernando Cabanillas, Peter McLaughlin, JR Redman, F Swan, Sundar Jagannath, EJ Freireich, Michael Fridrik, P. Salvador, WS Velasquez and Sen Pathak and has published in prestigious journals such as Blood and American Journal of Roentgenology.

In The Last Decade

FB Hagemeister

18 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)

1988 487 citations Fernando Cabanillas, P. Salvador et al. Blood profile →

Peers

Countries citing papers authored by FB Hagemeister

Since Specialization

Citations

This map shows the geographic impact of FB Hagemeister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by FB Hagemeister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites FB Hagemeister more than expected).

Fields of papers citing papers by FB Hagemeister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by FB Hagemeister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by FB Hagemeister. The network helps show where FB Hagemeister may publish in the future.

Co-authorship network of co-authors of FB Hagemeister

This figure shows the co-authorship network connecting the top 25 collaborators of FB Hagemeister. A scholar is included among the top collaborators of FB Hagemeister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with FB Hagemeister. FB Hagemeister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL) 2008 ·Blood ·Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez, FB Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin J. Shah, (unknown), (unknown), Fernando Cabanillas, Larry W. Kwak, Hagop M. Kantarjian, Michael Wang	10
2	Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma 1992 ·Blood ·Fernando Cabanillas, WS Velasquez, FB Hagemeister, Peter McLaughlin, JR Redman	32
3	Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma 1992 ·Blood ·Fernando Cabanillas, WS Velasquez, FB Hagemeister, Peter McLaughlin, JR Redman	38
4	Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy 1991 ·Blood ·WS Velasquez, (unknown), Sundar Jagannath, (unknown), (unknown), FB Hagemeister, Peter McLaughlin, F Swan, JR Redman, (unknown)	1
5	Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy 1991 ·Blood ·WS Velasquez, (unknown), Sundar Jagannath, (unknown), (unknown), FB Hagemeister, Peter McLaughlin, F Swan, JR Redman, (unknown)	45
6	Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data 1989 ·Blood ·WS Velasquez, Sundar Jagannath, (unknown), (unknown), (unknown), JR Redman, F Swan, FB Hagemeister, Peter McLaughlin, Fernando Cabanillas	4
7	Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data 1989 ·Blood ·WS Velasquez, S Jagannath, (unknown), (unknown), (unknown), JR Redman, F Swan, FB Hagemeister, Peter McLaughlin, Fernando Cabanillas	93
8	Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) 1988 ·Blood ·(unknown), Fernando Cabanillas, P. Salvador, Peter McLaughlin, Michael Fridrik, Stephen B. Tucker, Sundar Jagannath, FB Hagemeister, JR Redman, F Swan	20
9	Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) breakdown → 1988 ·Blood ·(unknown), Fernando Cabanillas, P. Salvador, Peter McLaughlin, Michael Fridrik, (unknown), Sundar Jagannath, FB Hagemeister, JR Redman, F Swan	487
10	Cytogenetic features of Hodgkin's disease suggest possible origin from a lymphocyte 1988 ·Blood ·Fernando Cabanillas, Sen Pathak, JM Trujillo, Grace Grant, Ann Cork, FB Hagemeister, (unknown), Peter McLaughlin, J R Redman, Ruth L. Katz	4
11	Cytogenetic features of Hodgkin's disease suggest possible origin from a lymphocyte 1988 ·Blood ·Fernando Cabanillas, Sen Pathak, José M. Trujillo, Grace Grant, Ann Cork, FB Hagemeister, (unknown), Peter McLaughlin, J R Redman, Ruth L. Katz	68
12	The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas 1987 ·Blood ·(unknown), (unknown), Sen Pathak, (unknown), (unknown), (unknown), Peter McLaughlin, FB Hagemeister, (unknown), A Goodacre	91
13	The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas 1987 ·Blood ·MS Lee, (unknown), (unknown), JM Trujillo, (unknown), (unknown), (unknown), FB Hagemeister, (unknown), (unknown)	9
14	Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males 1985 ·Blood ·(unknown), (unknown), Fernando Cabanillas, (unknown), FB Hagemeister, (unknown), G. E. Newell, (unknown), (unknown), (unknown)	2
15	Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males 1985 ·Blood ·(unknown), (unknown), Fernando Cabanillas, (unknown), FB Hagemeister, (unknown), G. E. Newell, (unknown), (unknown), (unknown)	126
16	Importance of initial mediastinal adenopathy in Hodgkin disease 1982 ·American Journal of Roentgenology ·(unknown), (unknown), FB Hagemeister, (unknown), (unknown), (unknown)	27
17	IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy 1982 ·Blood ·Fernando Cabanillas, FB Hagemeister, (unknown), EJ Freireich	216
18	IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy 1982 ·Blood ·Fernando Cabanillas, FB Hagemeister, GP Bodey, EJ Freireich	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact